FT
CRNX icon

Fiduciary Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fiduciary Trust’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341K Buy
9,379
+482
+5% +$21.5K ﹤0.01% 697
2025
Q4 		$414K Buy
8,897
+1,477
+20% +$65.8K ﹤0.01% 623
2025
Q3 		$309K Hold
7,420
– – ﹤0.01% 694
2025
Q2 		$213K Buy
7,420
+525
+8% +$16.2K ﹤0.01% 787
2025
Q1 		$231K Buy
+6,895
New +$258K ﹤0.01% 746

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fiduciary Trust's CRNX Position: Q1 2026 in Review

Fiduciary Trust increased its Crinetics Pharmaceuticals (CRNX) stake by 5.4% in Q1 2026, buying an estimated $21.5K and bringing the position to 9,379 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Fiduciary Trust first reported a position in CRNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $414K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Fiduciary Trust held 9,379 shares of Crinetics Pharmaceuticals worth $341K as of Q1 2026.
  • Fiduciary Trust bought 482 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $21.5K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Fiduciary Trust's portfolio in Q1 2026, its #697 holding.
  • Fiduciary Trust first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Fiduciary Trust's Crinetics Pharmaceuticals position peaked at $414K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.